Cagrilintide-Semaglutide Combination Achieves Unprecedented Weight Loss in Adults with Obesity

Obesity and overweight are chronic diseases affecting billions globally, significantly increasing the risk of type 2 diabetes, cardiovascular disease, and certain cancers. Current pharmacological treatments, including GLP-1 receptor agonists like semaglutide, have demonstrated substantial weight loss, but many individuals still struggle to achieve and maintain clinically meaningful reductions. This study addresses the critical need for more effective and potent therapeutic strategies to combat the rising prevalence of obesity and its associated health burdens.